Kymera Therapeutics

Join us on February 26th as we share our fourth quarter and full year financial results, along with the latest company updates: https://bit.ly/4kMWWFw

Our team came together to recognize the Lunar New Year with vibrant traditions, delicious food, and plenty of joy. ✨   As an employee-driven event organized by a group of Kymerians, including Ziyan Zhao, the celebration reflected what makes our community special: creating space to learn, connect, and celebrate together. From lion dancers 🦁 to interactive trivia, it was a meaningful way to welcome the Year of the Horse 🐎. Wishing everyone a happy, healthy, and prosperous new year! #Belong #LunarNewYear2026 #YearOfTheHorse

Behind every breakthrough is a story and today, we’re proud to celebrate the women in science who are writing theirs at Kymera. On this International Day of Women and Girls in Science, we honor the innovators, mentors, and trailblazers on our team who push boundaries and shape the future of STEM. Swipe to hear from a few of them – through reflections and advice, they share what drives their work, what they’ve learned along the way, and why representation in science matters.   #WomenInScience #WomenInSTEM

Tune in tomorrow to hear our CEO, Nello Mainolfi, discuss our novel approach in immunology and upcoming milestones across our industry-leading pipeline of oral degrader medicines at the Guggenheim Partners Biotech Summit. Listen to the live webcast here: https://bit.ly/4abvxJS

Meet Jared Gollob — Kymera’s Chief Medical Officer and a seasoned biopharmaceutical leader who oversees our clinical development organization. In this video, Jared discusses:  🔸 What excited him about Kymera’s breakthrough targeted protein degradation technology 🔸 How our oral medicines have the potential to transform treatment paradigms across a range of immuno‑inflammatory diseases   ➡️ Explore career opportunities to join our clinical development team: https://bit.ly/3LphRkK ➡️ Follow Kymera for more stories from our people and new roles! #ClinicalDevelopment #BiotechJobs #Hiring

Explore our upcoming investor events in February in our latest press release: https://bit.ly/3ZNnPiK

We’re pleased to share that the first patient has been dosed in our BREADTH Phase 2b clinical trial evaluating KT-621, our investigational, first-in-class, oral STAT6-targeted medicine for moderate to severe asthma.    This milestone reflects our commitment to advancing novel oral therapies with the potential to transform treatment paradigms for patients living with asthma and other immuno-inflammatory diseases. Read the full announcement: https://bit.ly/3Z6pfVu   #RevolutionizingImmunology #Asthma #BREADTH

🚀 Kymera is Hiring Interns & Co-Ops for Summer/Fall 2026! 🔬   We’re excited to announce the opening of our Intern and Co-Op roles across multiple functions. At Kymera, you will be fully integrated into project teams, contribute to real work, and gain exposure to the dynamic environment of a growing biotechnology company.   We are looking for: ✅ Highly motivated students currently enrolled in an academic program ✅ Strong analytical, scientific, or business skills ✅ Eagerness to learn, collaborate, and make an impact!   📍 All Roles are based in Watertown, MA  👉 Learn more and apply here: https://bit.ly/49RbZZy     #BiotechInternships #CoOp #BiotechCareers

Meet Mahta Mortezavi, MD — a leader at Kymera working to bring breakthrough science to patients through our Clinical Development team.   In this video, Matty reflects on: 🔸Why now is an exciting time to be at Kymera  🔸What the translation of TPD into the clinic means to her  🔸Her enthusiasm for the future of our clinical programs    ➡️ Explore opportunities to work with Matty here: https://bit.ly/3LphRkK ➡️ Follow Kymera for more stories from our people and new roles!   #ClinicalDevelopment #BiotechJobs #Hiring

We’re entering 2026 with exciting momentum and a clear vision.   Kymera is advancing an industry leading portfolio of oral immunology programs as we work toward transforming the treatment of immuno-inflammatory diseases for patients around the world.   With KT-621 Phase 2b studies in atopic dermatitis and asthma underway, a first-in-human study for KT-579 planned in 2026, and continued progress across our early discovery engine and partnered programs—driven by our team’s innovation and strong execution—we are well positioned for the year ahead.   Learn more in our recent press release and listen to the live webcast of our CEO Nello Mainolfi's presentation at #JPMHC26 today: https://bit.ly/4qCI8vr   #RevolutionizingImmunology #JPM2026